Guggenheim began coverage on shares of Tenax Therapeutics (NASDAQ:TENX – Free Report) in a research note released on Monday, Marketbeat reports. The brokerage issued a buy rating and a $16.00 price target on the specialty pharmaceutical company’s stock.
TENX has been the subject of a number of other research reports. StockNews.com initiated coverage on Tenax Therapeutics in a report on Thursday, September 26th. They set a “sell” rating for the company. William Blair started coverage on shares of Tenax Therapeutics in a research report on Monday, September 30th. They set an “outperform” rating for the company.
Get Our Latest Analysis on TENX
Tenax Therapeutics Stock Up 4.1 %
Tenax Therapeutics (NASDAQ:TENX – Get Free Report) last issued its quarterly earnings results on Tuesday, August 13th. The specialty pharmaceutical company reported ($1.83) EPS for the quarter, topping the consensus estimate of ($1.99) by $0.16. On average, research analysts forecast that Tenax Therapeutics will post -6.75 EPS for the current year.
About Tenax Therapeutics
Tenax Therapeutics, Inc develops and commercializes pharmaceutical products containing imatinib for the treatment of pulmonary arterial hypertension in the United States. The company develops TNX-101 (IV), TNX-102, and TNX-103 (levosimendan) that have completed phase II clinical trials for the treatment of patients with pulmonary hypertension associated with heart failure with preserved ejection fraction and associated pulmonary hypertension; and TNX-201 (imatinib), a tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia.
Featured Articles
- Five stocks we like better than Tenax Therapeutics
- How to Calculate Stock Profit
- Taiwan Semiconductor Stock: Buy Now or Wait for Earnings?
- Using the MarketBeat Dividend Yield Calculator
- Abbott’s Growth and Dividends Make It a Smart Portfolio Pick
- What is a Special Dividend?
- Citigroup Faces Growing Troubles: Could the Industry Be at Risk?
Receive News & Ratings for Tenax Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tenax Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.